Clinical trial
A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
NCT00793819 is registered in ClinicalTrials.gov with Watson Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
- Lead sponsor
- Watson Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2009
- Completion date
- October 31, 2009
- Enrollment
- 215 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.